Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price94.61 USD
Fair value130.00
Ethical score85.2/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-09-18Read Distribution94.61+0.0% to today
2026-08-19Read Markup97.19-2.7% to today
2026-07-02Read Distribution87.33+8.3% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Zimmer Biomet holds its Distribution at $94.61. Consolidating, no directional conviction, held for 19 days.
As held on the ledger · 2026-09-09
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 19 days
Price at the screen
$94.61
Valuation
22.96 trailing · 10.43 forward price to earnings
Values screen
PASS· score 85.2
Beta
0.47
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.56%
Below 33%
Interest-bearing debt is just 32.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.94%
Below 49%
Money owed to the company is 9.9% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 37% discount to our $130.00 fair value, narrow competitive moat, 4.80% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 37.4% margin of safety to the base estimate.
Third-party analyst targets: 21 covering, consensus None. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
New hips and knees meet steady demand
When a patient finally gets a new knee after years of pain the implant must fit exactly and last for decades. Zimmer Biomet designs and sells those devices worldwide.
The company grows revenue 9 percent a year and trades on a forward P/E of 10.1 times with a 30 percent margin of safety to fair value. It clears the ethical screen and holds a narrow moat in reconstructive orthopaedics.
Return on equity sits at just 6 percent and profit margins are 9 percent, so any slowdown in elective procedures or rise in competition would quickly pressure results. Analyst targets cluster near current prices.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ZBH trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99.
2026-08-19Markup · changed$97.19+11.3%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99.
2026-07-18Distribution$87.33+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (21 analysts) rates it hold, with a mean price target of $99.
2026-07-03Distribution$87.33+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$87.33Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
